Completed
Grazoprevir and Elbasvir in Patients with Stage 4 or 5 Chronic Kidney Disease
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Hepatitis C – Vanishing Disease? - Sammy Saab, MD, MPH | UCLA Digestive Diseases
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Decreasing Prevalence of Chronic Hepatitis C Infection, NHANES 2003 to 2010
- 3 Increasing Number of Hospitalizations related to HCV in Los Angeles County, 2007-2009
- 4 Extrahepatic Manifestations of Chronic Hepatitis C
- 5 Evolution of Hepatitis C Therapy Genotype 1
- 6 Hepatitis C: Achieving a Cure
- 7 Properties of Direct Acting Agents
- 8 Combination of Direct Acting Agents
- 9 Disappearing Special Populations
- 10 Cure vs Relapse Great Balance Act
- 11 Special Considerations
- 12 Resistance Associated Variants (RAV) General Principles
- 13 Resistance Testing
- 14 Treatment Regiments for Genotype 1 Patients
- 15 Treatment of non-Genotype 1 Patients
- 16 Grazoprevir and Elbasvir in Patients with Stage 4 or 5 Chronic Kidney Disease
- 17 Recommended Monitoring for patients after Antiviral Treatment
- 18 Improving the HCV Test and Cure Continuum: High Drug Costs are Not the Only Barrier
- 19 Model-Based Predictions The Changing Burden of Hepatitis C Virus Infection
- 20 Changes in CPT and MELD Scores from Baseline.
